Saturday 17 October 2026
Export MYGN’s income statement to Excel — free account
Myriad Genetics, Inc.
MYGN Healthcare Diagnostics & Research
Myriad Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $824.5 million, down 1.56% from fiscal 2024. In the quarter to June 2026, revenue fell 10.5%, EPS grew 87.1%, free cash flow grew 43.9% and total debt rose 103.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.98
0.37
−8.51%
Follow MYGN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (32.54%) | (76.73%) | (68.45%) | (72.52%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
5 | 4 | 5 | 4 | |
| (17.11%) | (47.61%) | (42.20%) | (44.27%) | ||
ROIC |
(19.92%) | (72.93%) | (71.53%) | (75.78%) | |
Return on Tangible Assets |
(42.14%) | (135.97%) | (116.98%) | (129.95%) | |
Average Days of Receivables |
49.55 | 54.51 | 51.04 | 52.19 | |
Free Cash Flow per Share |
(0.15) | (0.25) | (0.28) | (0.41) | |
Free Cash Flow |
(14.20) | (23.20) | (25.60) | (38.30) | |
Capital Expenditures |
(21.90) | (25.60) | (27.40) | (36.10) | |
| Other line items | |||||
Cash ROIC |
(2.63%) | (3.99%) | (4.02%) | (6.01%) | |
Accounts Receivable Turnover |
6.54 | 6.79 | 6.97 | 6.77 | |
Accounts Payable Turnover |
8.20 | 8.20 | 7.96 | 7.97 | |
Inventory Turnover |
8.48 | 8.86 | 8.53 | 8.46 | |
Average Days of Payables |
44.14 | 47.79 | 44.17 | 47.45 | |
Days of Inventory on Hand |
44.43 | 40.90 | 45.05 | 47.15 | |
Tax Rate |
0.01 | 0.00 | (0.07) | (0.06) | |
Research and Development Expense of Revenue |
13.12% | 12.83% | 12.95% | 13.84% | |
Selling, General and Administrative Expense of Revenue |
66.94% | 64.86% | 65.20% | 66.48% | |
Share Based Compensation of Revenue |
3.56% | 3.88% | 4.27% | 5.25% | |
Interest Coverage |
(6.01) | (28.18) | (36.88) | (61.85) | |
Operating CF/Net income |
(0.07) | (0.01) | 0.00 | 0.01 | |
Depreciation/Fixed assets |
0.54 | 3.38 | 3.27 | 3.73 | |
Capex/Depreciation |
(0.38) | (0.07) | (0.07) | (0.09) | |
Revenue per Share |
8.51 | 8.85 | 8.90 | 8.86 | |
Operating CF per Share |
0.08 | 0.03 | 0.02 | (0.02) | |
Capex per Share |
(0.23) | (0.27) | (0.30) | (0.39) | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.04 |
Columns are period end dates